New findings from a DETOUR2 substudy show that minimally invasive percutaneous transmural arterial bypass (PTAB) may offer a ...

Argo Biopharma begins patient dosing in phase II trials of siRNA therapy BW-40202: Shanghai, China Wednesday, April 22, 2026, 15:00 Hrs [IST] Argo Biopharmaceutical Co., Ltd. (Arg ...

Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced the first patient has been dosed in multiple Phase II studies of ...

A 2026 informational report on Quietum Plus ear ringing relief positioning, auditory nerve support ingredients, proprietary ...

Sedona-based Alternative to Meds Center highlights Glyphosate exposure, neurological health concerns, and more used in ...

Promising Late-Stage Drugs Signal A New Treatment Era Delveinsight. The generalized myasthenia gravis treatment pipeline ...

The mechanics of the onset of cancer or neurodegenerative disorders like Alzheimer's disease or ALS remain a mystery.

Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

Newer FDA-approved treatments for myasthenia gravis (MG) include FcRn blockers and complement inhibitors, which offer targeted symptom control beyond traditional steroids.

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant IgA antibodies in the glomerular mesangium. Now, researchers have found that ...

Complement pathway proteins are involved in immunoglobulin A-containing immune complex (IgA-IC) formation and deposition in the kidneys. Elevated complement factor H-related protein 1 (CFHR1) may be a ...